Drug utilization and medical expenses in psoriasis treatment at a dermatology hospital in Vietnam, 20192021
Keywords:
Health expense, medication utilization, psoriasis, use of medicines, VietnamAbstract
Introduction. Psoriasis is a persistent, chronic, inflammatory cutaneous disorder that recurs frequently and has negative impacts on the living quality of sufferers.
Methods. Data from the Inpatient and Outpatient Department medical records at Can Tho dermatology hospital were used to generate a descriptive statistics report on medicines and medical costs for psoriasis therapy in 2019-2021.
Results. The average number of prescription medications varied annually, averaging roughly 0.62±85.4% per prescription. Corticosteroids and calcipotriol were the most commonly recommended drugs for psoriasis. Antihistamines were the most often used medication, with over 12,000 instances among the 28,397 individuals studied. The peak in average per-treatment expenses occurred in 2021 when they fluctuated between US $120 and US $160. In contrast, examination expenses were the most costly, ranging from US $93-$107.
Conclusion. The bulk of psoriasis therapy treatments were topical agents, whose quantities rose progressively. Direct examination expenses accounted for the greatest proportion.
References
1. Heller MM, Wong JW, Nguyen TV, et al. Quality-of-life instruments: evaluation of the impact of psoriasis on patients. Dermatol Clin. 2012; 30(2): 281-91. doi: 10.1016/J. DET.2011.11.006.
2. Pearce DJ, Spencer L, Hu J, Balkrishnan R, Fleischer AB, Feldman SR. Class I topical corticosteroid use by psoriasis patients in an academic practice. J Dermatolog Treat. 2004; 15(4): 235-8. doi: 10.1080/09546630410033745.
3. Boehncke WH, Boehncke S, Schön MP. Managing comorbid disease in patients with psoriasis.
BMJ. 2010; 340(7739): 200. doi: 10.1136/BMJ. B5666.
4. Samarasekera E, Sawyer L, Parnham J, Smith CH. Assessment and management of psoriasis: summary of NICE guidance. BMJ. 2012 Oct; 345: e6712. doi:10.1136/BMJ.E6712.
5. Feldman SR, Fleischer J, Reboussin DM, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol. 1997; 37(4):564-569. doi:10.1016/S0190-9622(97)70172-5.
6. Lee S, Xie L, Wang Y, Vaidya N, Baser O. Comorbidity and economic burden among
moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population. J Med Econ. 2018; 21(6): 564-70.
doi: 10.1080/13696998.2018.1431921.
7. Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017; 76(3): 377-90. doi: 10.1016/J.JAAD.2016.07.064.
8. Nguyen PH, Dang TVK, Nguyen PT, Vo TMH, Nguyen TTM. 5-year inventory management of drug products using ABC-VEN analysis in the pharmacy store of a specialized public hospital in Vietnam. Pharmacia 2022; 69(2): 517-25.
doi:10.3897/PHARMACIA.69.E84348.
9. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002; 46(6): 850-60. doi: 10.1067/
MJD.2002.119669.
10. Akhyani M, Ehsani AH, Robati RM, Robati AM. The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol. 2007; 21(10): 1330-2. doi: 10.1111/J.1468-3083 .2007.02260.X.
11. Mashor M, Wong KW, Tey KE, Choon SE. A retrospective study on drug survival of biologic among patients with psoriasis seen in tertiary hospital in Johor Malaysia. Med J Malaysia. 2022 Nov; 77(6): 689-95.
12. Al Sawah S, Foster SA, Goldblum OM, et al. Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis. J Med Econ. 2017; 20(9): 982-90. doi: 10.1080/13696998.2017.1345749.
13. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum. 2005; 52(4): 1227-36. doi: 10.1002/art.20967.
14. Galimberti ML, Vacas AS, Hernández BA, Bollea Garlatti ML, Cura MJ, Galimberti RL. Medical resource consumption of moderate/severe psoriasis in a private health organization of Buenos Aires, Argentina. An Bras Dermatol. 2020; 95(1): 20-4. doi: 10.1016/J.ABD.2019.04.007.
15. Lee JH, Lee SM, Choi JH, et al. Factors influencing quality of life in patients with psoriasis in Korea. Eur J Dermatol. 2018; 28(5):678-80. doi: 10.1684/EJD.2018.3341.
16. Benites E, Carrillo E, Heras M. Effects of methotrexate and etanercept treatment in moderate and severe psoriasis. Medicine. 2022; 101(45): e31527. doi: 10.1097/ MD.0000000000031527.
17. Feldman SR, Zhao Y, Shi L, Tran MH. Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis. J Manag Care Spec Pharm. 2015; 21(10): 874-88. doi: 10.18553/JMCP.2015.21.10.874.
18. Feldman SR, Burudpakdee C, Gala S, Nanavaty M, Mallya UG. The economic burden of psoriasis: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2014; 14(5): 685705. doi: 10.1586/14737167.2014.933671.
19. Dreiher J, Weitzman D, Shapiro J, Davidovici B, Cohen AD. Psoriasis and chronic obstructive pulmonary disease: a case–control study. British Journal of Dermatology. 2008; 159(4): 956-60.
doi: 10.1111/J.1365-2133.2008.08749.X.
20. Ghasri P, Yentzer BA, Dabade TS, Feldman SR. Acitretin for the treatment of psoriasis: an assessment of national trends. J Drugs Dermatol. 2011 Aug; 10(8): 873-7. PMID: 21818508.
21. Bhuvana KB. Drug prescribing pattern of topical corticosteroids in dermatology unit of a tertiarycare hospital. Int J Med Sci Public Health Online. Published online 2015. doi: 10.5455/ ijmsph.2015.17052015351.
22. Augustin M, Schäfer I, Reich K, Glaeske G, Radtke M. Systemic treatment with corticosteroids in psoriasis--health care provision far beyond the S3-guidelines. J Dtsch Dermatol Ges. 2011; 9(10): 833-8. doi: 10.1111/J.16100387.2011.07713.X.
23. Boffa MJ. Methotrexate for psoriasis: current European practice. A postal survey. J Eur Acad Dermatol Venereol. 2005; 19(2): 196-202. doi:
10.1111/J.1468-3083.2004.01140.X.
24. Burgos-Pol R, Martínez-Sesmero JM, VenturaCerdá JM, Elías I, Caloto MT, Casado M. The Cost of Psoriasis and Psoriatic Arthritis in 5 European Countries: A Systematic Review. Actas Dermosifiliogr. 2016; 107(7): 577-90. doi: 10.1016/J.AD.2016.04.018.
25. Carrascosa JM, Pujol R, Daudén E, et al. A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol. 2006; 20(7) :840-5.
doi: 10.1111/J.1468-3083.2006.01659.X.
26. Evans C. Managed care aspects of psoriasis and psoriatic arthritis. Am J Manag Care. 2016 Jun; 22(8 Suppl): s238-43. PMID: 27356195.
27. Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013; 149(10): 1173-9. doi: 10.1001/
JAMADERMATOL.2013.5015.
28. Lee S, Xie L, Wang Y, Vaidya N, Baser O. Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population. J Manag Care Spec Pharm. 2018; 24(7): 654-63. doi: 10.18553/JMCP.2018.24.7.654.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.